Bryan Garnier - Eurofins Scientific Societe Europeenne EUROFINS SCIENTIFIC: Q3 IMS: Strong recovery after cyber attack | BUY | EUR465(+5%)

Report

Bryan Garnier

Bruno de La Rochebrochard

EUROFINS SCIENTIFIC: Q3 IMS: Strong recovery after cyber attack | BUY | EUR465(+5%)

EUROFINS SCIENTIFIC - BUY | EUR465(+5%)
Q3 IMS: Strong recovery after cyber attack

Organic revenue growth largely in line with expectations
Sufficient liquidity to carry out its strategy
Group financial situation remains tense but must now improve

28/10/2019 4 EN

Underlying

Eurofins Scientific Societe Europeenne

Eurofins Scientific is an international life sciences company operating in food & pharmaceutical products testings. Co. provides analytical testing services to clients from various industries including pharmaceutical, food, and environmental sectors. Co. offers analytical methods for evaluating the authenticity, origin, safety, identity, composition, and purity of biological substances & products. Co. verifies authenticity of products analyzed to detect dangerous components (pathogens, prions, pesticides, asbestos, mycotoxins, dioxins, toxic substances, etc.). Co. operates in Benelux, France, Germany, North America, Scandinavia, British Isles (U.K. & Republic of Ireland), & other countries.

See profile

FR0000038259 France

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Bruno de La Rochebrochard

Other Reports on these Companies

SmartInsider

Eurofins Scientific S.E: 1 director

A director at Eurofins Scientific S.E sold 400 shares at 54.720EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of...

Free Trial

March 13, 2024 March 13, 2024 1 EN

Bryan Garnier

EUROFINS SCIENTIFIC: FY guidance again upgraded after strongest H1 results | BUY | EUR125

EUROFINS SCIENTIFIC - BUY | EUR125 FY guidance again upgraded after strongest H1 results Results again supported by Covid activities FY guidance again revised upwards

July 27, 2022 July 27, 2022 1 EN

Bryan Garnier

EUROFINS SCIENTIFIC: Q1 IMS: Trends that remain largely positive | BUY | EUR125

EUROFINS SCIENTIFIC - BUY | EUR125 Q1 IMS: Trends that remain largely positive Good start, ahead expectation Guidance which sounds to us still conservative

April 21, 2022 April 21, 2022 1 EN

L'Oréal reports encouraging Q1 2024 sales figures

L'Oréal's Q1 sales were above market expectations. Excluding a technical one-off positive impact, sales grew 8.1% lfl over the quarter (consensus: +6.4%) thanks to strong performances in the mass market and Derma Beauty divisions. L'Oréal continued to outperform a still dynamic beauty market (+6%).

5h / 40m 5h / 40m 1 EN

Clement Genelot

Clement Genelot

Food Delivery: diverging growth/FCF profiles

Post TKWY and ROO's Q1 figures and ahead of DHER's publication, we note an improving growth trend in Q1. This growth will nevertheless have to rebalance towards orders as out-of-home food is also set to face disinflation this year. The ability to recreate HSD% growth will be the name of the 2024-25

5h / 51m 5h / 51m 1 EN

Cedric Rossi

Cedric Rossi

EssilorLux: in-line Q1 sales performance and good vibes ahead of Q2

Yesterday evening, EssilorLux unveiled Q1 sales up 5.5% FX-n to EUR6.34bn, fairly in line with CSSe (EUR6.38bn) despite a tough comp base and unfavourable calendar effect. We see room for accelerating trends given increased tailwinds from: 1/ pricing in frames (BGe: MSD price hike), 2/ the ramp-up

5h / 52m 5h / 52m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

EUROFINS SCIENTIFIC: Q3 IMS: Strong recovery after cyber attack | BUY | EUR465(+5%)

Eurofins Scientific S.E: 1 director

EUROFINS SCIENTIFIC: FY guidance again upgraded after strongest H1 results | BUY | EUR125

EUROFINS SCIENTIFIC: Q1 IMS: Trends that remain largely positive | BUY | EUR125

L'Oréal reports encouraging Q1 2024 sales figures

Food Delivery: diverging growth/FCF profiles

EssilorLux: in-line Q1 sales performance and good vibes ahead of Q2

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe